Impact of Glycemic Control on Risk of Infections in Patients with Type 2 Diabetes: A Population-Based Cohort Study

American Journal of Epidemiology

Volumn 186, Issue 2, 2017, Pages 227-236

  Mor, Anil ^a   Dekkers, Olaf M ^a,b   Nielsen, Jens S ^c   Beck Nielsen, Henning ^c   Sørensen, Henrik T ^a   Thomsen, Reimar W ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antiinfective agents; Glycemic control; Hemoglobin A1c; Infections; Type 2 diabetes mellitus

Indexed keywords

CEPHALOSPORIN; DICLOXACILLIN; FLUCLOXACILLIN; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; ANTIINFECTIVE AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

COHORT ANALYSIS; CONFIDENCE INTERVAL; DIABETES; DISEASE CONTROL; HEALTH RISK; HEMOGLOBIN; HOSPITAL SECTOR; INFECTIOUS DISEASE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMMUNITY TREATED INFECTION; CONTROLLED STUDY; DENMARK; DIABETIC PATIENT; FEMALE; GLYCEMIC CONTROL; HOSPITAL TREATED INFECTION; HUMAN; HYPERGLYCEMIA; INCIDENCE; INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; STAPHYLOCOCCUS INFECTION; ANALYSIS; COMMUNITY CARE; COMORBIDITY; COMPLICATION; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; HOSPITAL PATIENT; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK FACTOR; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

DENMARK;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BLOOD GLUCOSE; COHORT STUDIES; COMMUNITY HEALTH SERVICES; COMORBIDITY; DENMARK; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; INCIDENCE; INFECTION; INPATIENTS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS;

EID: 85029668305     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwx049     Document Type: Article

References (39)

1. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care. 2003;26(2):510-513.
2. Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, et al. Diabetes mellitus, fasting glucose, and risk of causespecific death. N Engl J Med. 2011;364(9):829-841.
3. Thomsen RW,Mor A. Diabetes and risk of community-acquired respiratory tract infection, urinary tract infections, and bacteraemia: a review. Open Infect Dis J. 2012;6(suppl 1:M2):27-39.
4. Muller LM, Gorter KJ, Hak E, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005;41(3):281-288.
5. Boyko EJ, Fihn SD, Scholes D, et al. Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women. Am J Epidemiol. 2005; 161(6):557-564.
6. Turina M, Fry DE, Polk HC Jr. Acute hyperglycemia and the innate immune system: clinical, cellular, and molecular aspects. Crit Care Med. 2005;33(7):1624-1633.
7. Schuetz P, Castro P, Shapiro NI. Diabetes and sepsis: preclinical findings and clinical relevance. Diabetes Care. 2011;34(3):771-778.
8. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24): 2560-2572.
9. Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2013;(11):CD008143.
10. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589.
11. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9139):854-865.
12. Laakso M, Cederberg H. Glucose control in diabetes: which target level to aim for? J InternMed. 2012;272(1):11-12.
13. Hamilton EJ, Martin N, Makepeace A, et al. Incidence and predictors of hospitalization for bacterial infection in community-based patients with type 2 diabetes: the Fremantle Diabetes Study. PLoS One. 2013;8(3):e60502.
14. Davis TM, Weerarathne T, Foong Y, et al. Communityacquired infections in type 2 diabetic patients and their nondiabetic partners. The Fremantle Diabetes Study. J Diabetes Complications. 2005;19(5):259-263.
15. Benfield T, Jensen JS, Nordestgaard BG. Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia. 2007;50(3):549-554.
16. Thomsen RW, Riis AH, Kjeldsen S, et al. Impact of diabetes and poor glycaemic control on risk of bacteraemia with haemolytic streptococci groups A, B, and G. J Infect. 2011; 63(1):8-16.
17. McKane CK, Marmarelis M, Mendu ML, et al. Diabetes mellitus and community-acquired bloodstream infections in the critically ill. J Crit Care. 2014;29(1):70-76.
18. Kornum JB, Thomsen RW, Riis A, et al. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care. 2008; 31(8):1541-1545.
19. Leegaard A, Riis A, Kornum JB, et al. Diabetes, glycemic control, and risk of tuberculosis: a population-based casecontrol study. Diabetes Care. 2011;34(12):2530-2535.
20. Hirji I, Andersson SW, Guo Z, et al. Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database. J Diabetes Complications. 2012;26(6):501-505.
21. Hirji I, Guo Z, Andersson SW, et al. Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD). J Diabetes Complications. 2012;26(6):513-516.
22. Lind M, Oden A, Fahlen M, et al. A systematic review of HbA1c variables used in the study of diabetic complications. Diabetes Metab Syndr. 2008;2(4):282-293.
23. Lynge E, Sandegaard JL, ReboljM. The Danish National Patient Register. Scand J PublicHealth. 2011;39(7 suppl):30-33.
24. Ehrenstein V, Antonsen S, Pedersen L. Existing data sources for clinical epidemiology: Aarhus University Prescription Database. Clin Epidemiol. 2010;2:273-279.
25. Grann AF, Erichsen R, Nielsen AG, et al. Existing data sources for clinical epidemiology: the Clinical Laboratory Information System (LABKA) research database at Aarhus University, Denmark. Clin Epidemiol. 2011;3:133-138.
26. Little RR. Glycated hemoglobin standardization-National Glycohemoglobin Standardization Program (NGSP) perspective. Clin Chem Lab Med. 2003;41(9):1191-1198.
27. WHOCollaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment 2011. Geneva, Switzerland: World Health Organization; 2011. http:// www.whocc.no/filearchive/publications/2011guidelines.pdf. Accessed July 2, 2016.
28. ThomsenRW, Riis A, Nørgaard M, et al. Rising incidence and persistently high mortality of hospitalized pneumonia: a 10-year population-based study in Denmark. J Intern Med. 2006; 259(4):410-417.
29. American Diabetes Association. Standards of Medical Care in Diabetes-2015: summary of revisions. Diabetes Care. 2015; 38(suppl 1):S4.
30. Bartelink ML, Hoek L, Freriks JP, et al. Infections in patients with type 2 diabetes in general practice. Diabetes Res Clin Pract. 1998;40(1):15-19.
31. Furnary AP, Zerr KJ, Grunkemeier GL, et al. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg. 1999;67(2):352-362.
32. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001; 345(19):1359-1367.
33. Arnold LW, Wang Z. The HbA1c and all-cause mortality relationship in patients with type 2 diabetes is J-shaped: a metaanalysis of observational studies. Rev Diabet Stud. 2014;11(2): 138-152.
34. Ostgren CJ, Sundstrom J, Svennblad B, et al. Associations of HbA1c and educational level with risk of cardiovascular events in 32,871 drug-treated patients with type 2 diabetes: a cohort study in primary care. Diabet Med. 2013;30(5): e170-e177.
35. Nichols GA, Joshua-Gotlib S, Parasuraman S. Glycemic control and risk of cardiovascular disease hospitalization and all-cause mortality. J Am Coll Cardiol. 2013;62(2):121-127.
36. Chiang HH, Tseng FY, Wang CY, et al. All-cause mortality in patients with type 2 diabetes in association with achieved hemoglobin A(1c), systolic blood pressure, and low-density lipoprotein cholesterol levels. PLoS One. 2014;9(10):e109501.
37. Carson AP, Fox CS, McGuire DK, et al. Low hemoglobin A1c and risk of all-cause mortality among US adults without diabetes. Circ Cardiovasc Qual Outcomes. 2010;3(6):661-667.
38. Kaspersen KA, Pedersen OB, Petersen MS, et al. Obesity and risk of infection: results from the Danish Blood Donor Study. Epidemiology. 2015;26(4):580-589.
39. Koch K, Søgaard M, Nørgaard M, et al. Socioeconomic inequalities in risk of hospitalization for community-acquired bacteremia: a Danish population-based case-control study. Am J Epidemiol. 2014;179(9):1096-1106.